Vera Therapeutics(VERA)
$30.48+0.45 (+1.50%)
VERA
Vera Therapeutics financials statements
$30.48
At close:+0.45 (+1.50%)
Want to see VERA full AI Analyst Report?
Vera Therapeutics (VERA) Ratios
948 Followers
Vera Therapeutics Ratios
VERA's free cash flow for Q3 2026 was $-99.18M. For the 2026 fiscal year, VERA's free cash flow was increased by $150.00K and operating cash flow was $-99.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 |
| Quick Ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 |
| Cash Ratio | 6.64 | 3.65 | 2.05 | 1.70 | 10.36 |
| Solvency Ratio | -2.30 | -1.94 | -1.30 | -1.65 | -2.29 |
| Operating Cash Flow Ratio | -4.51 | -5.31 | -4.13 | -2.64 | -3.08 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 598.67M | $ 572.69M | $ 98.16M | $ 71.17M | $ 68.38M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.08 | 0.31 | 0.24 | 0.06 |
| Debt-to-Equity Ratio | 0.13 | 0.09 | 0.53 | 0.41 | 0.07 |
| Debt-to-Capital Ratio | 0.11 | 0.09 | 0.35 | 0.29 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.08 | 0.33 | 0.24 | 0.07 |
| Financial Leverage Ratio | 1.22 | 1.14 | 1.73 | 1.71 | 1.20 |
| Debt Service Coverage Ratio | -38.72 | -18.94 | -24.35 | -89.63 | -1620.65 |
| Interest Coverage Ratio | -41.89 | -21.92 | -26.94 | -91.64 | -1720.10 |
| Debt to Market Cap | 0.02 | 0.02 | 0.08 | 0.05 | 0.01 |
| Interest Debt Per Share | 1.32 | 1.13 | 1.35 | 1.21 | 0.37 |
| Net Debt to EBITDA | 0.95 | 0.26 | -0.09 | 0.14 | 2.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.97% | 91.01% | 94.10% | 97.97% | 94.79% |
| Return on Assets (ROA) | -40.78% | -23.20% | -54.68% | -67.76% | -38.94% |
| Return on Equity (ROE) | -49.56% | -26.36% | -94.40% | -115.80% | -46.86% |
| Return on Capital Employed (ROCE) | -46.31% | -26.52% | -66.57% | -85.89% | -45.23% |
| Return on Invested Capital (ROIC) | -46.27% | -26.46% | -65.53% | -83.80% | -45.23% |
| Return on Tangible Assets | -40.78% | -23.20% | -54.68% | -67.76% | -38.94% |
| Earnings Yield | -9.21% | -6.50% | -14.61% | -17.32% | -9.08% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | -0.07 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 5173.42 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | -5173.42 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.75 | -2.43 | -2.16 | -2.54 | -1.76 |
| Free Cash Flow Per Share | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 |
| Dividend Paid and CapEx Coverage Ratio | -382.70 | -138.56 | -1463.19 | -1090.26 | 0.00 |
| Capital Expenditure Coverage Ratio | -382.70 | -138.56 | -1463.19 | -1090.26 | 0.00 |
| Operating Cash Flow Coverage Ratio | -3.12 | -2.46 | -1.72 | -2.16 | -4.82 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.43% | -5.80% | -14.04% | -13.16% | -6.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.87 | -15.38 | -6.84 | -5.77 | -11.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.38 | 4.05 | 6.46 | 6.69 | 5.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.46 | -17.25 | -7.12 | -7.60 | -15.14 |
| Price-to-Operating Cash Flow Ratio | -13.49 | -17.37 | -7.13 | -7.61 | -15.14 |
| Price-to-Earnings Growth (PEG) Ratio | -0.16 | -0.69 | 0.21 | -0.15 | 0.13 |
| Enterprise Value Multiple | -10.20 | -15.94 | -7.21 | -5.65 | -8.77 |
| Enterprise Value | 2.98B | 2.30B | 664.86M | 501.97M | 284.25M |
| EV to EBITDA | -10.20 | -15.94 | -7.21 | -5.65 | -8.77 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -12.31 | -16.97 | -7.21 | -7.42 | -11.99 |
| EV to Operating Cash Flow | -12.34 | -17.09 | -7.21 | -7.43 | -11.99 |
| Tangible Book Value Per Share | 9.41 | 10.43 | 2.38 | 2.89 | 5.18 |
| Shareholders’ Equity Per Share | 9.41 | 10.43 | 2.38 | 2.89 | 5.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.03 | 1.05 | 1.04 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.89 | 0.96 | 0.76 | 0.73 |
Currency in USD
